These and other actions carried out in Brazil corroborate the global demand of the CF community, which considers that CFTR modulators are the best treatment available, but the high prices of these drugs make them almost inaccessible outside the high-income countries [26]. The gene discussed is CFTR; the disease is cystic fibrosis.